Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01195662




Registration number
NCT01195662
Ethics application status
Date submitted
3/09/2010
Date registered
6/09/2010
Date last updated
29/12/2016

Titles & IDs
Public title
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Secondary ID [1] 0 0
2010-019798-13
Secondary ID [2] 0 0
MB102-077 ST
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Placebo matching Dapagliflozin

Experimental: Dapagliflozin 10 mg - Dapagliflozin 10 mg tablets

Placebo comparator: Placebo matching Dapagliflozin - Placebo tablets matching dapagliflozin tablets


Treatment: Drugs: Dapagliflozin
Tablets, Oral, 10 mg, once daily, Up to 12 weeks

Treatment: Drugs: Placebo matching Dapagliflozin
Tablets, Oral, 0 mg, once daily, Up to 12 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants
Timepoint [1] 0 0
Baseline to Week 12
Primary outcome [2] 0 0
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants
Timepoint [2] 0 0
Baseline to Week 12
Secondary outcome [1] 0 0
Adjusted Mean Change From Baseline in 24-hour Ambulatory Systolic Blood Pressure at Week 12 Last Observation Carried Forward (LOCF)
Timepoint [1] 0 0
Baseline, Week 12
Secondary outcome [2] 0 0
Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 12 Week Double-Blind Treatment Period - Randomized Participants
Timepoint [2] 0 0
Baseline to Week 12
Secondary outcome [3] 0 0
Adjusted Mean Change From Baseline in 24-hr Ambulatory Diastolic Blood Pressure at Week 12 (LOCF)
Timepoint [3] 0 0
Baseline, Week 12
Secondary outcome [4] 0 0
Adjusted Mean Change From Baseline in Serum Uric Acid at Week 12 in Double-Blind Treatment Period - Randomized Participants
Timepoint [4] 0 0
Baseline, Week 12
Secondary outcome [5] 0 0
Number of Participants With Deaths,Serious Adverse Events (SAEs), Adverse Events (AEs), Hypoglycemia Events, Discontinuation Due to AEs, SAEs and Hypoglycemia, During the 12 Week Double Blind Period, Including Data After Rescue
Timepoint [5] 0 0
Baseline to last dose of 12 weeks of double blind medication plus 30 days if SAE or plus 4 days if AE/hypoglycemic event
Secondary outcome [6] 0 0
Number of Participants With Marked Chemistry Laboratory Abnormalities in 12 Week Double Blind Treatment Period, Including Data After Rescue
Timepoint [6] 0 0
Baseline (Day 1) to last dose double blind medication (Week 12) plus 4 days
Secondary outcome [7] 0 0
Number of Participants With Elevated Liver Laboratory Tests in Participants Treated With Double Blind 10 mg Dapagliflozin or Placebo , Including Data After Rescue
Timepoint [7] 0 0
Baseline (Day 1) to last dose double blind medication (Week 12) Plus 30 days
Secondary outcome [8] 0 0
Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 12 (LOCF), Including Data After Rescue
Timepoint [8] 0 0
Baseline, Week 12
Secondary outcome [9] 0 0
Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue
Timepoint [9] 0 0
Baseline (Day 1), Week 12

Eligibility
Key inclusion criteria
* Written informed consent
* Males and females, 18 to 89 years old, with type 2 diabetes with inadequate glycemic control HbA1c between 7-10.5% and uncontrolled hypertension Systolic Blood Pressure (SBP) 140-165 and Diastolic Blood Pressure (DBP) 85-105
* Subjects must have a mean 24 hr blood pressure = 130/80 determined by Ambulatory Blood Pressure Monitoring (ABPM) within 1 week prior to Day 1 visit
* Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks [12 wks for Thiazolidinedione (TZD)] or a stable daily dose of insulin, as a monotherapy or in combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1 additional antihypertensive medication for at least 4 weeks
* C-peptide = 0.8 ng/mL
* Body Mass Index = 45.0 kg/m2
* Serum creatinine < 1.50 mg/dL for men or < 1.40 mg/dL for women
Minimum age
18 Years
Maximum age
89 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Aspartate aminotransferase (AST) and /or Alanine aminotransferase (ALT) > 3.0*upper limit of normal (ULN)
* Serum total bilirubin = 1.5*ULN
* Creatinine kinase > 3*ULN
* Symptoms of severely uncontrolled diabetes
* History of malignant or accelerated hypertension
* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2013
Sample size
Target
Accrual to date
Final
2245
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Camperdown
Recruitment hospital [2] 0 0
Local Institution - Heidelberg
Recruitment hospital [3] 0 0
Local Institution - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3081 - Heidelberg
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
North Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
New Brunswick
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Canada
State/province [39] 0 0
Saskatchewan
Country [40] 0 0
Colombia
State/province [40] 0 0
Quindio
Country [41] 0 0
Colombia
State/province [41] 0 0
Santander
Country [42] 0 0
Colombia
State/province [42] 0 0
Barranquilla
Country [43] 0 0
Colombia
State/province [43] 0 0
Bogota
Country [44] 0 0
Czech Republic
State/province [44] 0 0
Beroun
Country [45] 0 0
Czech Republic
State/province [45] 0 0
Cheb
Country [46] 0 0
Czech Republic
State/province [46] 0 0
Havirov
Country [47] 0 0
Czech Republic
State/province [47] 0 0
Krnov
Country [48] 0 0
Czech Republic
State/province [48] 0 0
Liberec
Country [49] 0 0
Czech Republic
State/province [49] 0 0
Ostrava
Country [50] 0 0
Czech Republic
State/province [50] 0 0
Prague 1
Country [51] 0 0
Czech Republic
State/province [51] 0 0
Praha 4
Country [52] 0 0
Denmark
State/province [52] 0 0
Copenhagen
Country [53] 0 0
Denmark
State/province [53] 0 0
Frederiksberg
Country [54] 0 0
Denmark
State/province [54] 0 0
Gentofte
Country [55] 0 0
Denmark
State/province [55] 0 0
Slagelse
Country [56] 0 0
Finland
State/province [56] 0 0
Helsinki
Country [57] 0 0
Finland
State/province [57] 0 0
Kerava
Country [58] 0 0
Finland
State/province [58] 0 0
Kokkola
Country [59] 0 0
Finland
State/province [59] 0 0
Oulu
Country [60] 0 0
Germany
State/province [60] 0 0
Bavaria
Country [61] 0 0
Germany
State/province [61] 0 0
Nordrhein-Westfalen
Country [62] 0 0
Germany
State/province [62] 0 0
Bad Kreuznach
Country [63] 0 0
Germany
State/province [63] 0 0
Berlin
Country [64] 0 0
Germany
State/province [64] 0 0
Dortmund
Country [65] 0 0
Germany
State/province [65] 0 0
Dresden
Country [66] 0 0
Germany
State/province [66] 0 0
Karlsruhe
Country [67] 0 0
Germany
State/province [67] 0 0
Kothen
Country [68] 0 0
Germany
State/province [68] 0 0
Kronshagen
Country [69] 0 0
Germany
State/province [69] 0 0
Langenfeld
Country [70] 0 0
Germany
State/province [70] 0 0
Lueneburg
Country [71] 0 0
Germany
State/province [71] 0 0
Magdeburg
Country [72] 0 0
Germany
State/province [72] 0 0
Mainz
Country [73] 0 0
Germany
State/province [73] 0 0
Mannheim
Country [74] 0 0
Germany
State/province [74] 0 0
Saarbruecken
Country [75] 0 0
Germany
State/province [75] 0 0
Wuestensachsen
Country [76] 0 0
Hungary
State/province [76] 0 0
Heves
Country [77] 0 0
Hungary
State/province [77] 0 0
Budapest
Country [78] 0 0
Hungary
State/province [78] 0 0
Eger
Country [79] 0 0
Hungary
State/province [79] 0 0
Kisvarda
Country [80] 0 0
Hungary
State/province [80] 0 0
Miskolc
Country [81] 0 0
Hungary
State/province [81] 0 0
Nyiregyhaza
Country [82] 0 0
Hungary
State/province [82] 0 0
Satoraljaujhely
Country [83] 0 0
Hungary
State/province [83] 0 0
Sopron
Country [84] 0 0
Hungary
State/province [84] 0 0
Szeged
Country [85] 0 0
Hungary
State/province [85] 0 0
Szekszard
Country [86] 0 0
India
State/province [86] 0 0
Andhra Pradesh
Country [87] 0 0
India
State/province [87] 0 0
Karnataka
Country [88] 0 0
India
State/province [88] 0 0
Karnatka
Country [89] 0 0
India
State/province [89] 0 0
Madhya Pradesh
Country [90] 0 0
India
State/province [90] 0 0
Maharashtra
Country [91] 0 0
India
State/province [91] 0 0
New Delhi
Country [92] 0 0
India
State/province [92] 0 0
Rajasthan
Country [93] 0 0
India
State/province [93] 0 0
Tamil Nadu
Country [94] 0 0
India
State/province [94] 0 0
Tamilnadu
Country [95] 0 0
India
State/province [95] 0 0
Chennai Tamilnadu
Country [96] 0 0
India
State/province [96] 0 0
Hyderabad
Country [97] 0 0
India
State/province [97] 0 0
Nagpur
Country [98] 0 0
India
State/province [98] 0 0
Trivandrum
Country [99] 0 0
Ireland
State/province [99] 0 0
Dublin
Country [100] 0 0
Ireland
State/province [100] 0 0
Galway
Country [101] 0 0
Mexico
State/province [101] 0 0
Coahuila
Country [102] 0 0
Mexico
State/province [102] 0 0
Distrito Federal
Country [103] 0 0
Mexico
State/province [103] 0 0
Jalisco
Country [104] 0 0
Mexico
State/province [104] 0 0
Morelos
Country [105] 0 0
Mexico
State/province [105] 0 0
Nuevo Leon
Country [106] 0 0
Mexico
State/province [106] 0 0
Sinaloa
Country [107] 0 0
Mexico
State/province [107] 0 0
Yucatan
Country [108] 0 0
Mexico
State/province [108] 0 0
Chihuahua
Country [109] 0 0
Mexico
State/province [109] 0 0
Del. Benito Juarez
Country [110] 0 0
Mexico
State/province [110] 0 0
Delegacion Tlalpan
Country [111] 0 0
Mexico
State/province [111] 0 0
San Luis Potosi
Country [112] 0 0
Poland
State/province [112] 0 0
Bialystok
Country [113] 0 0
Poland
State/province [113] 0 0
Chrzanow
Country [114] 0 0
Poland
State/province [114] 0 0
Elblag
Country [115] 0 0
Poland
State/province [115] 0 0
Gdansk
Country [116] 0 0
Poland
State/province [116] 0 0
Gdynia
Country [117] 0 0
Poland
State/province [117] 0 0
Kamieniec Zabkowicki
Country [118] 0 0
Poland
State/province [118] 0 0
Katowice
Country [119] 0 0
Poland
State/province [119] 0 0
Kielce
Country [120] 0 0
Poland
State/province [120] 0 0
Krakow
Country [121] 0 0
Poland
State/province [121] 0 0
Lodz
Country [122] 0 0
Poland
State/province [122] 0 0
Lublin
Country [123] 0 0
Poland
State/province [123] 0 0
Ostroda
Country [124] 0 0
Poland
State/province [124] 0 0
Poznan
Country [125] 0 0
Poland
State/province [125] 0 0
Warsaw
Country [126] 0 0
Poland
State/province [126] 0 0
Warszawa
Country [127] 0 0
Poland
State/province [127] 0 0
Wroclaw
Country [128] 0 0
Poland
State/province [128] 0 0
Zabrze
Country [129] 0 0
Puerto Rico
State/province [129] 0 0
Fajard
Country [130] 0 0
Puerto Rico
State/province [130] 0 0
Ponce
Country [131] 0 0
Puerto Rico
State/province [131] 0 0
San Juan
Country [132] 0 0
Romania
State/province [132] 0 0
Bihor
Country [133] 0 0
Romania
State/province [133] 0 0
Jud. Bihor
Country [134] 0 0
Romania
State/province [134] 0 0
Jud. Timis
Country [135] 0 0
Romania
State/province [135] 0 0
Mures
Country [136] 0 0
Romania
State/province [136] 0 0
Prahova
Country [137] 0 0
Romania
State/province [137] 0 0
Timis
Country [138] 0 0
Romania
State/province [138] 0 0
Bucuresti
Country [139] 0 0
Romania
State/province [139] 0 0
Cluj-Napoca
Country [140] 0 0
Romania
State/province [140] 0 0
Satu Mare
Country [141] 0 0
Romania
State/province [141] 0 0
Sibiu
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Ayrshire
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Cambridgeshire
Country [144] 0 0
United Kingdom
State/province [144] 0 0
West Midlands
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Wiltshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied
Trial website
https://clinicaltrials.gov/study/NCT01195662
Trial related presentations / publications
Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016 Mar;4(3):211-220. doi: 10.1016/S2213-8587(15)00417-9. Epub 2015 Nov 27. Erratum In: Lancet Diabetes Endocrinol. 2016 Mar;4(3):e3. Lancet Diabetes Endocrinol. 2016 Mar;4(3):e3. doi: 10.1016/S2213-8587(15)00467-2.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01195662